U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07334145) titled 'Effect of SGLT2 Inhibitors on Anemic CKD Patients' on Dec. 31, 2025.
Brief Summary: anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD
Study Start Date: Jan. 01
Study Type: OBSERVATIONAL
Condition:
Anemia in CKD Patients
Intervention:
DRUG: SGLT2 inhibitor
prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to ...